Skip to main content
Premium Trial:

Request an Annual Quote

Quotient Limited Gets CE Mark for Coronavirus Antibody Microarray

NEW YORK — Quotient Limited said on Friday that it has received CE marking for its SARS-CoV-2 antibody microarray test.

The MosaiQ COVID-19 Antibody Microarray is designed to detect human immunoglobulin G and M antibodies against SARS-CoV-2. It runs on the company's CE-marked Mosaiq automated testing system.

Quotient, headquartered in Eysins, Switzerland, said the assay has demonstrated 100 sensitivity and 99.8 percent specificity and was able to detect antibodies early in seroconversion in clinical testing.

Earlier this year, Quotient received CE marking for its serological disease screening microarray.